Deerfield Management Company, L.P. (Series C) Aquestive Therapeutics, Inc. Call Options Transaction History
Deerfield Management Company, L.P. (Series C)
- $5.38 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding AQST
# of Institutions
122Shares Held
46.8MCall Options Held
517KPut Options Held
207K-
Bratton Capital Management, L.P. Fort Worth, TX9.81MShares$35.8 Million100.0% of portfolio
-
Vr Adviser, LLC New York, NY5.56MShares$20.3 Million2.87% of portfolio
-
Black Rock Inc. New York, NY5.45MShares$19.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.26MShares$15.6 Million0.0% of portfolio
-
Franklin Resources Inc San Mateo, CA2.77MShares$10.1 Million0.0% of portfolio
About Aquestive Therapeutics, Inc.
- Ticker AQST
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,350,700
- Market Cap $195M
- Description
- Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual f...